Penicillamine

CHEMBL1430 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
149.2 g/mol
LogP
-1.8
Phase
4

This medication treats rheumatoid arthritis, Wilson's disease, and cystinuria by binding and removing harmful substances.

Khối lượng phân tử

149,2100 g/mol

LogP

-1,80

TPSA

64,30 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)(S)[C@@H](N)C(=O)O

InChI

InChI=1S/C5H11NO2S/c1-5(2,9)3(6)4(7)8/h3,9H,6H2,1-2H3,(H,7,8)/t3-/m0/s1

Molecular Formula

C5H11NO2S

HBD / HBA

3 / 4

Liên kết có thể quay

2

Nguyên tử nặng

9

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This medication treats rheumatoid arthritis, Wilson's disease, and cystinuria by binding and removing harmful substances.

Yes, Penicillamine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1430. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5852. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.